Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (395)	1/1/1999 6:39:00 AM
From: Henry Niman	Respond to of 4474

Mike, I just skimmed the patent and didn't see Epogen mentioned, but the patent is fairly broad.

To: Mike McFarland who wrote (395)	1/1/1999 7:25:00 AM
From: Henry Niman	Respond to of 4474

I think that I skimmed the patent too quickly. It is quite broad.

To: Mike McFarland who wrote (395)	1/1/1999 7:50:00 AM
From: Henry Niman	Respond to of 4474

Mike, I started of Transcription Regulation table under New Therapeutics at biocognizance.com So far it just has the Science abstract, Bloomberg comments, and Aria patent, but will have more soon.

To: Mike McFarland who wrote (395)	1/1/1999 12:28:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 4474

Mike: Thanks very much for raising this question. It's going to be an important one to have asked. Here's claim one...... We claim: 1. A composition, comprising: (a) recombinant AAV virions which comprise an AAV vector containing a nucleic acid molecule encoding erythropoietin operably linked to control elements that direct the transcription and translation thereof; and (b) a pharmaceutically acceptable excipient. This language clearly covers the ARIA work. I was surprised to see that the priority date was '96, sort of a fresh one. OTOH, here's the abstract..... The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved. Clearly, "sustained, high-level expression of a delivered nucleotide sequence" is not in the spirit of the ARIA work. It'll be interesting! Rick